No Data
No Data
Insider Sale: See Remarks of $TVGN Sells 71,273 Shares
Tevogen Bio Announces The Filing Of A New Patent With The USPTO For Its Under-Development T Cell Vaccine
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Express News | D. Boral Capital Initiates Coverage On Tevogen Bio Holdings With Buy Rating, Announces Price Target of $10
Tevogen Bio Holdings Analyst Ratings